77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

作者：Y. Cheng, Bai-Yu Liu, L. Wu, T. Zhang, K. Wang, L. Miao, Jinhai Wu, H. Wang, J. Fang, X. Li, weichen zhang, Y. Hu, X. Mei, Yaobang Song, ChunXue Wu, J. Zhu, Yunchang Xin, Y. Chen, G. Han, Jin-xiong Ye · 发表于：Immuno-Oncology Technology · 年份：2022 · DOI：10.1016/j.iotech.2022.100181 · 被引用次数：5 · 研究领域：Cancer Immunotherapy and Biomarkers、Peptidase Inhibition and Analysis、Immunotherapy and Immune Responses

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) plays an important role in tumor immunosurveillance in addition to well-established immunosuppressive checkpoint receptors such as PD-1 and CTLA-4. We report the preliminary safety and anti-tumor activity of IBI939 (anti-TIGIT mAb) in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with previously untreated locally advanced unresectable or metastatic PD-L1-selected NSCLC.